Clinical experience with 99mTc-DMSA (dimercaptosuccinic acid), a new renal-imaging agent.
Results are reported from the clinical evaluation of a new radiopharmaceutical for renal imaging, 99mTc-DMSA (dimercaptosuccinic acid). Sixty-five patients were studied and six of these patients' scintiphotos are illustrated. The physical characteristics of 99mTc and the mercurial-like kinetics of the chelate produced high-resolution scintiphotos of the renal parenchyma in patients of all ages and with a variety of disease entities. The commercial availability of the material in kit form permits its usage in all nuclear medicine facilities.
D000038:Abscess / Q000175:diagnosis; D000293:Adolescent; D000328:Adult; D002614:Chelating Agents; D002648:Child; D002675:Child, Preschool; D005260:Female; D006417:Hematuria / Q000175:diagnosis; D006801:Humans; D006869:Hydronephrosis / Q000175:diagnosis; D006977:Hypertension, Renal / Q000175:diagnosis; D007668:Kidney / Q000002:abnormalities / Q000293:injuries; D007674:Kidney Diseases / Q000175:diagnosis*; D007676:Kidney Failure, Chronic / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D007690:Polycystic Kidney Diseases / Q000175:diagnosis; D011704:Pyelonephritis / Q000175:diagnosis; D011877:Radionuclide Imaging; D013386:Succinates; D013438:Sulfhydryl Compounds; D013667:Technetium; D001750:Urinary Bladder, Neurogenic / Q000175:diagnosis; D014718:Vesico-Ureteral Reflux / Q000175:diagnosis
D002614:Chelating Agents; D013386:Succinates; D013438:Sulfhydryl Compounds; D013667:Technetium